New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
11:33 EDTAPOL, SVU, INFY, MU, PCYCOptions with decreasing implied volatility: APOL SVU INFY MU PCYC
News For APOL;SVU;INFY;MU;PCYC From The Last 14 Days
Check below for free stories on APOL;SVU;INFY;MU;PCYC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 19, 2014
14:09 EDTMUMicron volatility elevated into Q4 an outlook
Micron September weekly call option implied volatility is at 67, October weekly is at 54, October is at 41. November is at 39, January is at 38; compared to its 26-week average of 38 according to Track Data, suggesting large near term price movement into the expected release of Q4 results on September 25.
11:23 EDTMUStocks with call strike movement; YHOO MU
Subscribe for More Information
September 18, 2014
07:17 EDTAPOLBMO Capital to hold a conference
14th Annual Back to School Education Conference to be held in New York on September 18 with webcasted company presentations to begin at 8 am; not all company presentations may be webcasted. Webcast Link
06:45 EDTMUMobile DRAM bit growth to reach 37.5% in 2H14, DigiTimes Research reports
Subscribe for More Information
05:34 EDTINFYInfosys expands partnership with Microsoft
Subscribe for More Information
September 16, 2014
09:36 EDTMUActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL NFLX TSLA YHOO FB PBR MU AA TWTR WMT
07:03 EDTPCYCPharmacyclics VA contract worth $6 per share, says William Blair
Subscribe for More Information
September 15, 2014
11:56 EDTMUStocks with call strike movement; MU GILD
Subscribe for More Information
September 14, 2014
18:10 EDTMUMicron looks to expand to autos and wearables, WSJ says
Subscribe for More Information
September 11, 2014
08:28 EDTPCYCPharmacyclics VA contract has ceiling of $3.81B, says JPMorgan
JPMorgan says the Veterans Affairs contract won by Pharmacyclics for Imbruvica has a ceiling price of $3.81B over the entire 5-year period, and that actual sales will depend on the demand the drug generates. The firm notes Imbruvica’s contracted price has been negotiated for year one, and that the VA will either renegotiate the price each year or continue as is. JPMorgan keeps an Overweight rating on shares of Pharmacyclics.
September 10, 2014
14:29 EDTPCYCPharmacyclics Veterans Affairs contract worth up to $17 per share, says Goldman
Today, the U.S. Department of Veterans Affairs awarded Pharmacyclics a contract worth up to $3.8B over the next five years to supply its cancer drug, Imbruvica. Goldman said the contract could be worth up to $17 per share if fully realized and views it as an unexpected windfall for the company.
14:07 EDTPCYCPharmacyclics ibrutinib designated as orphan treatment of follicular lymphoma
Subscribe for More Information
13:11 EDTPCYCPharmacyclics climbs after leukemia drug wins VA contract
Shares of drug maker Pharmacyclics (PCYC) are rallying after a federal government website revealed that the company had won a contract that could be worth up to $3.8B. However, RBC Capital is warning that the deal is not as lucrative as it sounds and will not lead analysts to significantly raise their estimates for the company. WHAT'S NEW: A contract for Phamacyclics' Imbruvica drug, a treatment for chronic lymphocytic leukemia, was disclosed earlier today. The contract from Veterans Affairs, which has an award date of September 4, was revealed in a notice posted today to Federal Business Opportunities website and has a potential value of $3.809B, according to the posting. ANALYST REACTION: In a note to investors today, RBC Capital analyst Michael Yee wrote that the news is positive, but not to the extent that the size of the deal would suggest. Pharmacyclics is indicating that the size of the deal has been significantly misrepresented, Yee reported. Additionally, the order may not be a major surprise to analysts, since it is expected that the government will place orders for oncology drugs, he stated. Although Pharmacyclics is on pace to beat third quarter expectations, the order revealed today is unlikely to lead analysts to significantly raise their estimates, Yee stated. He kept a Sector Perform rating on the shares. PRICE ACTION: In early afternoon trading, Pharmacyclics advanced 5.5% to $125.
12:24 EDTPCYCPharmacyclics VA contract not likely to change estimates, says RBC Capital
Subscribe for More Information
10:58 EDTPCYCPharmacyclics rises after VA contract award revealed
Shares of drugmaker Pharmacyclics are rising after a contract for its Imbruvica drug that was previously awarded by the Department of Veterans Affairs was disclosed. The contract, which has an award date of September 4, was revealed in an award notice posted today today to Federal Business Opportunities website and has a potential value of $3.809B, according to the posting. Pharmacyclics shares are up 6.5% to $126.35 in morning trading following the circulation of the FBO site posting.
10:51 EDTPCYCPharmacyclics receives contract up to $3B from Department of Veterans Affairs
Subscribe for More Information
10:44 EDTMUMicron mentioned positively at Raymond James
08:32 EDTAPOLBofA/Merrill education/prof svcs analyst has analyst/industry conference call
Subscribe for More Information
September 9, 2014
07:22 EDTMURaymond James to hold a conference
North American Equities Conference to be held in London, England on September 9.
September 8, 2014
10:23 EDTINFYSyntel names Christopher Mason as North America sales head
Syntel (SYNT) announced earlier today the appointment of Christopher Mason as Head - North America Sales, effective September 8. Prior to joining Syntel, Mason served as Global Head of Business Development for the global sourcing division at Infosys (INFY).
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use